Leuven

• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• Open-label study to evaluate metreleptin in children under 6 years of age with generalised lipodystrophy Ended
  2022-501781-22-00 5 2024-02-09 Generalised lipodystrophy
• Effect of cannabidiol on muscle recovery following a single bout of resistance exercise. Ended
  2024-513768-24-00 3 2024-01-29 Healthy individuals
• A clinical study of MK-6194 for the treatment of vitiligo (MK-6194-007) Ended
  2023-503502-37-00 4 2024-01-24 Non segmental vitiligo
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• Clindamycin pharmacokinetics during obstetric or fetal surgery Ended
  2023-503653-35-00 6 2023-12-11 Prophylaxis (antibiotics) during maternal or fetal surgery
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis Ended
  2022-503005-38-00 4 2023-12-04 Ulcerative Colitis
• A MULTICENTER OPEN LABEL 3 MONTH SAFETY STUDY WITH TRADIPITANT IN PATIENTS WITH IDIOPATHIC OR DIABETIC GASTROPARESIS Ended
  2023-503802-35-00 5 2023-11-29 Idiopathic or diabetic gastroparesis with moderate to severe nausea.
• A trial to learn if different doses of REGN17092 are safe in healthy adults Ended
  2023-505041-52-00 1 2023-11-28 SARS-CoV-2 (COVID-19)
• A study to determine how BI 907828 (Brigimadlin) is taken up in the tumor (Phase 0) and to determine the highest dose of BI 907828 (Brigimad … Ended
  2023-506409-20-00 3 2023-11-24 Glioblastoma
• A Multiple-Ascending-Dose Study of MK-4318 in Healthy Participants Ended
  2023-507512-12-00 3 2023-11-16 Pain
• A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa Ended
  2022-502370-17-00 4 2023-11-14 Hidradenitis suppurativa
• A phase IV, randomized double blinded placebo-controlled study on the barrier restoring capacity of Dupilumab in type 2 airway disease: CRSw … Ended
  2023-504014-30-00 6 2023-11-14 chronic rhinosinusitis with nasal polyps
• A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to s … Ended
  2022-502540-12-00 5 2023-11-09 Refractory Status Epilepticus (RSE)
• Routine versus selective protamine administration to reduce bleeding complications after transcatheter aortic valve implantation Ended
  2023-504205-36-00 11 2023-11-01 Aortic stenosis
• Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA … Ended
  2023-503830-27-00 4 2023-10-17 Large B-Cell Lymphoma (LBCL)
• Pilot study RCT anti-TNF Adalimumab versus placebo in fasciotomy Dupuytren contracture Ended
  2023-503701-11-00 5 2023-10-16 Dupuytren Disease
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-501621-20-00 5 2023-10-02 Prurigo Nodularis
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal canc … Ended
  2023-503356-27-00 4 2023-09-07 Metastatic colorectal cancer that is resistant to the currently approv

Showing 937–960 of 1,135 trials